CommentaryEB 1089, a novel vitamin D Analog with strong antiproliferative and differentiation-inducing effects on target cells
References (58)
- et al.
Differing shapes of 1α,25-dihydroxyvitamin D3 function as ligands for the D-binding protein, nuclear receptor and membrane receptor: A status report
J Steroid Biochem Mol Biol
(1996) - et al.
Steroid hormone modulation of vitamin D receptor levels in human MG-63 osteosarcoma cells
Biochem Biophys Res Commun
(1994) - et al.
Retinoic acid modulation of 1,25(OH)2 vitamin D3 receptors and bioresponse in bone cells: Species difference between rat and mouse
Biochem Biophys Res Commun
(1985) - et al.
Distinct conformational changes induced by 20-epi analogues of 1α,25-dihydroxyvitamin D3 are associated with enhanced activation of the vitamin D receptor
J Biol Chem
(1995) - et al.
Metabolism of the vitamin D analog EB 1089: Identification of in vivo and in vitro liver metabolites and their biological activities
Biochem Pharmacol
(1997) - et al.
A novel vitamin D analog with two double bonds in its side chain. A potent inducer of osteoblastic cell differentiation
Biochem Pharmacol
(1996) - et al.
Differential effects of 1,25-dihydroxyvitamin D3-analogs on osteoblast-like cells and on in vitro bone resorption
J Steroid Biochem Mol Biol
(1995) - et al.
EB 1089, a novel vitamin D analogue, has strong antiproliferative and differentiation inducing effects on cancer cells
J Steroid Biochem Mol Biol
(1993) - et al.
The 1,25-dihydroxyvitamin D3 (VD) analogues MC 903, EB 1089 and KH 1060 activate the VD receptor: Homodimers show higher ligand sensitivity than heterodimers with retinoid X receptors
J Steroid Biochem Mol Biol
(1994) - et al.
Studies on two new vitamin D analogs, EB 1089 and KH 1060: Effects on bone resorption and osteoclast recruitment in vitro
Bone
(1995)
Effects of 1,25-dihydroxyvitamin D3 and its analogues on induction of apoptosis in breast cancer cells
J Steroid Biochem Mol Biol
Cytotoxic effects of 1α,25-dihydroxyvitamin D3 and synthetic vitamin D3 analogues on a glioma cell line
Cancer Lett
Inhibition of insulin-like growth factor-1-stimulated growth of human breast cancer cells by 1,25-dihydroxyvitamin D3 and the vitamin D3 analogue EB 1089
Eur J Cancer
1α,25-Dihydroxyvitamin D3 up-regulates expression of the osteoclast integrin αvβ3
J Biol Chem
1,25-Dihydroxyvitamin D3 increases epidermal growth factor receptors and transforming growth factor-β-like activity in a bone-derived cell line
J Biol Chem
1α,25(OH)2 Vitamin D3-regulated expression of the eukaryotic genome
Nutr Rev
Noncalcemic actions of 1,25-dihydroxyvitamin D3 and clinical applications
Bone
Vitamin D regulated gene expression
Crit Rev Eukaryot Gene Expr
Estrogen regulation of the nuclear 1,25-dihydroxyvitamin D3 receptor in rat liver and kidney
Endocrinology
Mechanisms of nuclear signalling by vitamin D3. Interplay with retinoid and thyroid hormone signalling
Eur J Biochem
Genomic mechanisms involved in the pleiotropic actions of 1,25-dihydroxyvitamin D3
Biochem J
The need for new vitamin D analogues: Mechanisms of action and clinical applications
Vitamin D and breast cancer: The therapeutic potential of new vitamin D analogues
Endocr Relat Cancer
The anti-proliferative effect of vitamin D3 analogues is not mediated by inhibition of the AP-1 pathway, but may be related to promoter selectivity
Oncogene
Comparative effects of 1,25-dihydroxyvitamin D3 and EB 1089 on mouse renal and intestinal 25-hydroxyvitamin D3-24-hydroxylase
J Bone Miner Res
Pharmacokinetic studies of vitamin D analogues: Relationship to vitamin D binding protein (DBP)
Endocrine
Selective biological response by target organs (intestine, kidney and bone) to 1,25-dihydroxyvitamin D, and two analogues
Cancer Res
Structure-function relationships in the vitamin D endocrine system
Endocr Rev
The antiproliferative and differentiation-inducing effects of vitamin D analogues are not determined by the binding affinity for the vitamin D receptor alone
Cited by (81)
Vitamin D Signaling Modulators in Cancer Therapy
2016, Vitamins and HormonesCitation Excerpt :MART-10 shows more potent than 1,25D3 in inhibiting cell proliferation in prostate cancer and breast cancer (Chiang et al., 2014, 2012; Flanagan et al., 2009). Seocalcitol (EB1089) and 20-epi-1,25D3 with modifications of the side chain of 1,25D3 are degraded more slowly than 1,25D3, leading to more prolong exposure of these analogs to the tissues (Hansen & Maenpaa, 1997; Kissmeyer et al., 1997; Shankar et al., 1997; Zella, Meyer, Nerenz, & Pike, 2009). Lexicalcitol (KH1060) is more effective in stabilizing VDR against degradation than 1,25D3 (Jaaskelainen, Ryhanen, Mahonen, DeLuca, & Maenpaa, 2000; van den Bemd, Pols, Birkenhager, & van Leeuwen, 1996).
Mechanisms for the selective actions of Vitamin D analogs
2011, Vitamin D: Two-Volume SetA new insight into the role of rat cytochrome P450 24A1 in metabolism of selective analogs of 1α,25-dihydroxyvitamin D<inf>3</inf>
2011, Archives of Biochemistry and BiophysicsCitation Excerpt :All these analogs were found to have remarkable biological properties when compared to 1, for some of them sufficiently promising to enter clinical drug development [22–25]. In particular, analog 6 (EB1089) has been extensively studied including its metabolism [26–30]. It was shown that 6 was metabolized into two metabolites identified as C26-hydroxy-6 and C26a-hydroxy-6 and the enzyme responsible for its metabolism was not CYP24A1 [27].
Mechanisms for the selective actions of vitamin D analogs
2011, Vitamin D